IRIS/Inhalation unit risks
Jump to navigation
Jump to search
[show] |
---|
Question
What are the Inhalation unit risks according to the IRIS database?
Answer
Inhalation unit risks
Obs | Substance | CASRN | Precursor Effect/ Tumor Type | Extrapolation Method | Unit | Inhalation unit risks | Study Route | IRIS identifier |
---|---|---|---|---|---|---|---|---|
1 | Acenaphthene | 83-32-9 | Not Assessed under the IRIS program. | |||||
2 | Acenaphthylene | 208-96-8 | Not Assessed under the IRIS program. | |||||
3 | Acephate | 30560-19-1 | Not Assessed under the IRIS program. | |||||
4 | Acetaldehyde | 75-07-0 | Nasal squamous cell carcinoma or adenocarcinoma | Linearized multistage-variable exposure input form (extra risk) | per µg/m3 | 2.2x10-6 | Inhalation | |
5 | Acetochlor | 34256-82-1 | Not Assessed under the IRIS program. | |||||
6 | Acetone | 67-64-1 | Not Assessed under the IRIS program. | |||||
7 | Acetonitrile | 75-05-8 | Not Assessed under the IRIS program. | |||||
8 | Acetophenone | 98-86-2 | Not Assessed under the IRIS program. | |||||
9 | Acetyl chloride | 75-36-5 | Not Assessed under the IRIS program. | |||||
10 | Acifluorfen, sodium | 62476-59-9 | Not Assessed under the IRIS program. | |||||
11 | Acrolein | 107-02-8 | Not Assessed under the IRIS program. | |||||
12 | Acrylamide | 79-06-1 | thyroid tumors and tunica vaginalis mesotheliomas | Multistage model with linear extrapolation from the point of departure (BMDL), summed risk. | per µg /m3 | 1x10-4 | Oral, drinking water | |
13 | Acrylic acid | 79-10-7 | Not Assessed under the IRIS program. | |||||
14 | Acrylonitrile | 107-13-1 | Respiratory cancer | Average relative risk | per µg /m3 | 6.8x10-5 | Inhalation | |
15 | Adiponitrile | 111-69-3 | Not Assessed under the IRIS program. | |||||
16 | Alachlor | 15972-60-8 | Not Assessed under the IRIS program. | |||||
17 | Alar | 1596-84-5 | Not Assessed under the IRIS program. | |||||
18 | Aldicarb | 116-06-3 | Not Assessed under the IRIS program. | |||||
19 | Aldicarb sulfone | 1646-88-4 | Not Assessed under the IRIS program. | |||||
20 | Aldrin | 309-00-2 | Liver carcinoma | Linearized multistage procedure, extra risk | per µg /m3 | 4.9x10-3 | Oral, Diet | |
21 | Ally | 74223-64-6 | Not Assessed under the IRIS program. | |||||
22 | Allyl alcohol | 107-18-6 | Not Assessed under the IRIS program. | |||||
23 | Allyl chloride | 107-05-1 | Not Assessed under the IRIS program. | |||||
24 | Aluminum phosphide | 20859-73-8 | Not Assessed under the IRIS program. | |||||
25 | Amdro | 67485-29-4 | Not Assessed under the IRIS program. | |||||
26 | Ametryn | 834-12-8 | Not Assessed under the IRIS program. | |||||
27 | 4-Aminopyridine | 504-24-5 | Not Assessed under the IRIS program. | |||||
28 | Amitraz | 33089-61-1 | Not Assessed under the IRIS program. | |||||
29 | Ammonia | 7664-41-7 | Not Assessed under the IRIS program. | |||||
30 | Ammonium acetate | 631-61-8 | Not Assessed under the IRIS program. | |||||
31 | Ammonium methacrylate | 16325-47-6 | Not Assessed under the IRIS program. | |||||
32 | Ammonium sulfamate | 7773-06-0 | Not Assessed under the IRIS program. | |||||
33 | Aniline | 62-53-3 | Not Assessed under the IRIS program. | |||||
34 | ortho-Anisidine | 90-04-0 | Not Assessed under the IRIS program. | |||||
35 | Anthracene | 120-12-7 | Not Assessed under the IRIS program. | |||||
36 | Antimony | 7440-36-0 | Not Assessed under the IRIS program. | |||||
37 | Antimony trioxide | 1309-64-4 | Not Assessed under the IRIS program. | |||||
38 | Apollo | 74115-24-5 | Not Assessed under the IRIS program. | |||||
39 | Aramite | 140-57-8 | Neoplastic liver nodules and carcinomas | Linearized multistage procedure, extra risk | per µg/m3 | 7.1x10-6 | Oral, Diet | |
40 | Aroclor 1016 | 12674-11-2 | Not Assessed under the IRIS program. | |||||
41 | Aroclor 1248 | 12672-29-6 | Not Assessed under the IRIS program. | |||||
42 | Aroclor 1254 | 11097-69-1 | Not Assessed under the IRIS program. | |||||
43 | Arsenic, inorganic | 7440-38-2 | Lung cancer | Absolute-risk linear model | per µg/m3 | 4.3x10-3 | Inhalation, Occupational exposure | |
44 | Arsine | 7784-42-1 | Not Assessed under the IRIS program. | |||||
45 | Asbestos | 1332-21-4 | Lung cancer and mesothelioma | Additive risk of lung cancer and mesothelioma, using relative risk model for lung cancer and absolute risk model for mesothelioma | per f/mL | 2.3x10-1 | Inhalation, Occupational exposure | |
46 | Assure | 76578-14-8 | Not Assessed under the IRIS program. | |||||
47 | Asulam | 3337-71-1 | Not Assessed under the IRIS program. | |||||
48 | Atrazine | 1912-24-9 | Not Assessed under the IRIS program. | |||||
49 | Avermectin B1 | 65195-55-3 | Not Assessed under the IRIS program. | |||||
50 | Azobenzene | 103-33-3 | Abdominal cavity sarcomas | Linearized multistage procedure, extra risk | per µg /m3 | 3.1x10-5 | Oral, Diet | |
51 | Barium and Compounds | 7440-39-3 | Not Assessed under the IRIS program. | |||||
52 | Barium cyanide | 542-62-1 | Not Assessed under the IRIS program. | |||||
53 | Baygon | 114-26-1 | Not Assessed under the IRIS program. | |||||
54 | Bayleton | 43121-43-3 | Not Assessed under the IRIS program. | |||||
55 | Baythroid | 68359-37-5 | Not Assessed under the IRIS program. | |||||
56 | Benefin | 1861-40-1 | Not Assessed under the IRIS program. | |||||
57 | Benomyl | 17804-35-2 | Not Assessed under the IRIS program. | |||||
58 | Bentazon (Basagran) | 25057-89-0 | Not Assessed under the IRIS program. | |||||
59 | Benz[a]anthracene | 56-55-3 | Not Assessed under the IRIS program. | |||||
60 | Benzaldehyde | 100-52-7 | Not Assessed under the IRIS program. | |||||
61 | Benzene | 71-43-2 | Leukemia | Low-dose linearity utilizing maximum likelihood estimates | per µg /m3 | 2.2x10-6 | Inhalation | |
62 | Benzene | 71-43-2 | Leukemia | Low-dose linearity utilizing maximum likelihood estimates | per µg /m3 | 7.8x10-6 | Inhalation | |
63 | Benzidine | 92-87-5 | Bladder tumors | One-hit with time factor, extra risk | per µg /m3 | 6.7x10-2 | Inhalation, Occupational exposure | |
64 | Benzo[a]pyrene (BaP) | 50-32-8 | Not Assessed under the IRIS program. | |||||
65 | Benzo[b]fluoranthene | 205-99-2 | Not Assessed under the IRIS program. | |||||
66 | Benzo[g,h,i]perylene | 191-24-2 | Not Assessed under the IRIS program. | |||||
67 | Benzo[k]fluoranthene | 207-08-9 | Not Assessed under the IRIS program. | |||||
68 | Benzoic acid | 65-85-0 | Not Assessed under the IRIS program. | |||||
69 | Benzotrichloride | 98-07-7 | Not Assessed under the IRIS program. | |||||
70 | Benzyl chloride | 100-44-7 | Not Assessed under the IRIS program. | |||||
71 | Beryllium and compounds | 7440-41-7 | Lung cancer | Relative risk | per µg /m3 | 2.4x10-3 | Inhalation, Occupational exposure | |
72 | Bidrin | 141-66-2 | Not Assessed under the IRIS program. | |||||
73 | Biphenthrin | 82657-04-3 | Not Assessed under the IRIS program. | |||||
74 | 1,1-Biphenyl | 92-52-4 | Not Assessed under the IRIS program. | |||||
75 | Bis(2-chloro-1-methylethyl) ether | 108-60-1 | Not Assessed under the IRIS program. | |||||
76 | Bis(2-chloroethoxy)methane | 111-91-1 | Not Assessed under the IRIS program. | |||||
77 | Bis(chloroethyl)ether (BCEE) | 111-44-4 | Hepatomas | Linearized multistage procedure, extra risk | per µg /m3 | 3.3x10-4 | Oral, Gavage followed by diet | |
78 | Bis(chloromethyl)ether (BCME) | 542-88-1 | Respiratory tract tumors | Linearized multistage procedure, extra risk | per µg /m3 | 6.2x10-2 | Inhalation | |
79 | Bisphenol A. | 80-05-7 | Not Assessed under the IRIS program. | |||||
80 | Boron and Compounds | 7440-42-8 | Not Assessed under the IRIS program. | |||||
81 | Bromate | 15541-45-4 | Information reviewed but value not estimated. Refer to IRIS Summary. | |||||
82 | Brominated dibenzofurans | NA | Not Assessed under the IRIS program. | |||||
83 | Bromobenzene | 108-86-1 | Not Assessed under the IRIS program. | |||||
84 | Bromochloromethane | 74-97-5 | Not Assessed under the IRIS program. | |||||
85 | Bromodichloromethane | 75-27-4 | Not Assessed under the IRIS program. | |||||
86 | p-Bromodiphenyl ether | 101-55-3 | Not Assessed under the IRIS program. | |||||
87 | Bromoform | 75-25-2 | Neoplastic lesions in the large intestine | Linearized multistage procedure, extra risk | per µg /m3 | 1.1x10-6 | Oral, Gavage in corn oil | |
88 | Bromomethane | 74-83-9 | Not Assessed under the IRIS program. | |||||
89 | Bromotrichloromethane | 75-62-7 | Not Assessed under the IRIS program. | |||||
90 | Bromoxynil | 1689-84-5 | Not Assessed under the IRIS program. | |||||
91 | Bromoxynil octanoate | 1689-99-2 | Not Assessed under the IRIS program. | |||||
92 | 1,3-Butadiene | 106-99-0 | Leukemia | Linear extrapolation from LEC01 (0.254 ppm); LEC01 derived from linear relative rate model (RR = 1 + (B)(x)) using lifetable analysis with leukemia incidence data; an adjustment factor of 2 was applied. | per µg /m3 | 3x10-5 | Inhalation | |
93 | n-Butanol | 71-36-3 | Not Assessed under the IRIS program. | |||||
94 | Butyl benzyl phthalate | 85-68-7 | Not Assessed under the IRIS program. | |||||
95 | Butylate | 2008-41-5 | Not Assessed under the IRIS program. | |||||
96 | t-Butylchloride | 507-20-0 | Not Assessed under the IRIS program. | |||||
97 | Butylphthalyl butylglycolate (BPBG) | 85-70-1 | Not Assessed under the IRIS program. | |||||
98 | Cacodylic acid | 75-60-5 | Not Assessed under the IRIS program. | |||||
99 | Cadmium | 7440-43-9 | Lung, trachea, bronchus cancer deaths | Two stage; only first affected by exposure; extra risk | per µg /m3 | 1.8x10-3 | Inhalation, Exposure in the workplace | |
100 | Calcium cyanide | 592-01-8 | Not Assessed under the IRIS program. | |||||
101 | Caprolactam | 105-60-2 | Not Assessed under the IRIS program. | |||||
102 | Captafol | 2425-06-1 | Not Assessed under the IRIS program. | |||||
103 | Captan | 133-06-2 | Not Assessed under the IRIS program. | |||||
104 | Carbary | l63-25-2 | Not Assessed under the IRIS program. | |||||
105 | Carbofuran1 | 563-66-2 | Not Assessed under the IRIS program. | |||||
106 | Carbon disulfide | 75-15-0 | Not Assessed under the IRIS program. | |||||
107 | Carbon tetrachloride | 56-23-5 | Pheochromocytoma | Log-probit model with linear extrapolation from the POD (LEC10). | per µg /m3 | 6x10-6 | Inhalation | |
108 | Carbonyl sulfide | 463-58-1 | Not Assessed under the IRIS program. | |||||
109 | Carbosulfan | 55285-14-8 | Not Assessed under the IRIS program. | |||||
110 | Carboxin | 5234-68-4 | Not Assessed under the IRIS program. | |||||
111 | Cerium Oxide and Cerium Compounds | 1306-38-3 | Not Assessed under the IRIS program. | |||||
112 | Chloral hydrate | 302-17-0 | Not Assessed under the IRIS program. | |||||
113 | Chloramben | 133-90-4 | Not Assessed under the IRIS program. | |||||
114 | Chlordane (Technical) | 12789-03-6 | Hepatocellular carcinoma | Linearized multistage procedure, extra risk | per µg /m3 | 1x10-4<7sup> | Oral, Diet | |
115 | Chlordecone (Kepone) | 143-50-0 | Information reviewed but value not estimated. Refer to IRIS Summary. | |||||
116 | Chlorimuron-ethyl | 90982-32-4 | Not Assessed under the IRIS program. | |||||
117 | Chlorine | 7782-50-5 | Not Assessed under the IRIS program. | |||||
118 | Chlorine cyanide | 506-77-4 | Not Assessed under the IRIS program. | |||||
119 | Chlorine dioxide | 10049-04-4 | Not Assessed under the IRIS program. | |||||
120 | Chlorite (sodium salt) | 7758-19-2 | Not Assessed under the IRIS program. | |||||
121 | 1-Chloro-1,1-difluoroethane | 75-68-3 | Not Assessed under the IRIS program. | |||||
122 | 2-Chloroacetophenone | 532-27-4 | Not Assessed under the IRIS program. | |||||
123 | p-Chloroaniline | 106-47-8 | Not Assessed under the IRIS program. | |||||
124 | Chlorobenzene | 108-90-7 | Not Assessed under the IRIS program. | |||||
125 | Chlorobenzilate | 510-15-6 | Not Assessed under the IRIS program. | |||||
126 | 1-Chlorobutane | 109-69-3 | Not Assessed under the IRIS program. | |||||
127 | 2-Chlorobutane | 78-86-4 | Not Assessed under the IRIS program. | |||||
128 | Chlorocyclopentadiene | 41851-50-7 | Not Assessed under the IRIS program. | |||||
129 | Chlorodifluoromethane | 75-45-6 | Not Assessed under the IRIS program. | |||||
130 | Chloroform | 67-66-3 | Hepatocellular carcinoma | Linearized multistage procedure, extra risk | per µg /m3 | 2.3x10-5 | Oral, Gavage | |
131 | Chloromethyl methyl ether (CMME) | 107-30-2 | Not Assessed under the IRIS program. | |||||
132 | beta-Chloronaphthalene | 91-58-7 | Not Assessed under the IRIS program. | |||||
133 | 2-Chlorophenol | 95-57-8 | Not Assessed under the IRIS program. | |||||
134 | p-Chlorophenyl methyl sulfide | 123-09-1 | Not Assessed under the IRIS program. | |||||
135 | p-Chlorophenyl methyl sulfone | 98-57-7 | Not Assessed under the IRIS program. | |||||
136 | p-Chlorophenyl methyl sulfoxide | 934-73-6 | Not Assessed under the IRIS program. | |||||
137 | Chloroprene | 126-99-8 | alveolar/ bronchiolar adenoma or carcinoma; hemangioma/ hemangiosarcoma (all organs); mammary gland adenocarcinoma, carcinoma, or adenoacanthoma; forestomach squamous cell papilloma or carcinoma; hepatocellular adenoma or carcinoma; Harderian gland adenoma or carcinoma; skin sarcoma; and Zymbal's gland carcinoma | Multistage model with linear extrapolation from the point of departure (BMDL), summed risk. | per µg /m3 | 3x10-4 | Inhalation | |
138 | Chlorothalonil | 1897-45-6 | Not Assessed under the IRIS program. | |||||
139 | o-Chlorotoluene | 95-49-8 | Not Assessed under the IRIS program. | |||||
140 | Chlorpropham | 101-21-3 | Not Assessed under the IRIS program. | |||||
141 | Chlorpyrifos | 2921-88-2 | Not Assessed under the IRIS program. | |||||
142 | Chlorsulfuron | 64902-72-3 | Not Assessed under the IRIS program. | |||||
143 | Chromium(III), insoluble salts | 16065-83-1 | Not Assessed under the IRIS program. | |||||
144 | Chromium(VI) | 18540-29-9 | Lung cancer | Multistage, extra risk | per µg /m3 | 1.2x10-2 | Inhalation, Occupational exposure | |
145 | Chrysene | 218-01-9 | Not Assessed under the IRIS program. | |||||
146 | Coke oven emissions | 8007-45-2 | Respiratory cancer | Linearized multistage procedure | per µg /m3 | 6.2x10-4 | Inhalation, Occupational | |
147 | Copper | 7440-50-8 | Not Assessed under the IRIS program. | |||||
148 | Copper cyanide | 544-92-3 | Not Assessed under the IRIS program. | |||||
149 | Creosote | 8001-58-9 | Not Assessed under the IRIS program. | |||||
150 | Crotonaldehyde | 123-73-9 | Not Assessed under the IRIS program. | |||||
151 | Cumene | 98-82-8 | Not Assessed under the IRIS program. | |||||
152 | Cyanazine | 21725-46-2 | Not Assessed under the IRIS program. | |||||
153 | Cyanide, free | 57-12-5 | Not Assessed under the IRIS program. | |||||
154 | Cyanogen | 460-19-5 | Not Assessed under the IRIS program. | |||||
155 | Cyanogen bromide | 506-68-3 | Not Assessed under the IRIS program. | |||||
156 | Cyclohexane | 110-82-7 | Not Assessed under the IRIS program. | |||||
157 | Cyclohexanone | 108-94-1 | Not Assessed under the IRIS program. | |||||
158 | Cyclohexylamine | 108-91-8 | Not Assessed under the IRIS program. | |||||
159 | Cyhalothrin/Karate | 68085-85-8 | Not Assessed under the IRIS program. | |||||
160 | Cypermethrin | 52315-07-8 | Not Assessed under the IRIS program. | |||||
161 | Cyromazine | 66215-27-8 | Not Assessed under the IRIS program. | |||||
162 | Dacthal | 1861-32-1 | Not Assessed under the IRIS program. | |||||
163 | Dalapon, sodium salt | 75-99-0 | Not Assessed under the IRIS program. | |||||
164 | Danitol | 39515-41-8 | Not Assessed under the IRIS program. | |||||
165 | 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) | 1163-19-5 | Not Assessed under the IRIS program. | |||||
166 | Demeton | 8065-48-3 | Not Assessed under the IRIS program. | |||||
167 | Di (2-ethylhexyl)phthalate (DEHP) | 117-81-7 | Not Assessed under the IRIS program. | |||||
168 | Di(2-ethylhexyl)adipate | 103-23-1 | Not Assessed under the IRIS program. | |||||
169 | 2,4-Diaminotoluene | 95-80-7 | Not Assessed under the IRIS program. | |||||
170 | Diazomethane | 334-88-3 | Not Assessed under the IRIS program. | |||||
171 | Dibenz[a,h]anthracene | 53-70-3 | Not Assessed under the IRIS program. | |||||
172 | Dibenzofuran | 132-64-9 | Not Assessed under the IRIS program. | |||||
173 | 1,2-Dibromo-3-chloropropane (DBCP) | 96-12-8 | Not Assessed under the IRIS program. | |||||
174 | 1,4-Dibromobenzene | 106-37-6 | Not Assessed under the IRIS program. | |||||
175 | Dibromochloromethane | 124-48-1 | Not Assessed under the IRIS program. | |||||
176 | Dibromodichloromethane | 594-18-3 | Not Assessed under the IRIS program. | |||||
177 | p,p'-Dibromodiphenyl ether | 2050-47-7 | Not Assessed under the IRIS program. | |||||
178 | 1,2-Dibromoethane | 106-93-4 | Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas | Multistage-Weibull model; linear extrapolation from lower 95% confidence limit on dose associated with extra risk (adjusted for background) at point of departure at lower end of data range. | per µg /m3 | 6x10-4 | Inhalation | |
179 | 1,2-Dibromoethane | 106-93-4 | Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas | Multistage-Weibull model; linear extrapolation from lower 95% confidence limit on dose associated with extra risk (adjusted for background) at point of departure at lower end of data range. | per µg /m3 | 3x10-4 | Inhalation | |
180 | Dibutyl phthalate | 84-74-2 | Not Assessed under the IRIS program. | |||||
181 | Dicamba | 1918-00-9 | Not Assessed under the IRIS program. | |||||
182 | Dichloroacetic acid | 79-43-6 | Information reviewed but value not estimated. Refer to IRIS Summary. | |||||
183 | 1,3-Dichlorobenzene | 541-73-1 | Not Assessed under the IRIS program. | |||||
184 | 1,4-Dichlorobenzene | 106-46-7 | Not Assessed under the IRIS program. | |||||
185 | 1,2-Dichlorobenzene | 95-50-1 | Not Assessed under the IRIS program. | |||||
186 | 3,3'-Dichlorobenzidine | 91-94-1 | Not Assessed under the IRIS program. | |||||
187 | Dichlorodifluoromethane | 75-71-8 | Not Assessed under the IRIS program. | |||||
188 | p,p'-Dichlorodiphenyl dichloroethane (DDD) | 72-54-8 | Not Assessed under the IRIS program. | |||||
189 | p,p'-Dichlorodiphenyldichloroethylene (DDE) | 72-55-9 | Not Assessed under the IRIS program. | |||||
190 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | Liver tumors, benign and malignant | Linear multistage procedure, extra risk | per µg /m3 | 9.7x10-5 | Oral,Diet | |
191 | 1,2-Dichloroethane | 107-06-2 | Hemangiosarcomas | Linearized multistage procedure, extra risk | per µg /m3 | 2.6x10-5 | Oral,Gavage | |
192 | 1,1-Dichloroethane | 75-34-3 | Not Assessed under the IRIS program. | |||||
193 | trans-1,2-Dichloroethylene | 156-60-5 | Not Assessed under the IRIS program. | |||||
194 | cis-1,2-Dichloroethylene | 156-59-2 | Not Assessed under the IRIS program. | |||||
195 | 1,1-Dichloroethylene (1,1-DCE) | 75-35-4 | Information reviewed but value not estimated. Refer to IRIS Summary. | |||||
196 | Dichloromethane | 75-09-2 | Hepatocellular carcinomas or adenomas, bronchoalveolar carcinomas or adenomas | Multistage model with linear extrapolation from the point of departure (BMDL10) | per µg /m3 | 1x10-8 | Inhalation | |
197 | 2,4-Dichlorophenol | 120-83-2 | Not Assessed under the IRIS program. | |||||
198 | 4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB) | 94-82-6 | Not Assessed under the IRIS program. | |||||
199 | 2,4-Dichlorophenoxyacetic acid (2,4-D) | 94-75-7 | Not Assessed under the IRIS program. | |||||
200 | 1,2-Dichloropropane | 78-87-5 | Not Assessed under the IRIS program. | |||||
201 | 2,3-Dichloropropanol | 616-23-9 | Not Assessed under the IRIS program. | |||||
202 | 1,3-Dichloropropene | 542-75-6 | Bronchioalveolar adenoma | Linearized multistage model, extra risk | per µg /m3 | 4x10-6 | Inhalation | |
203 | Dichlorvos | 62-73-7 | Not Assessed under the IRIS program. | |||||
204 | Dicofol | 115-32-2 | Not Assessed under the IRIS program. | |||||
205 | Dieldrin | 60-57-1 | Liver carcinoma | Linearized multistage procedure, extra risk | per µg /m3 | 4.6x10-3 | Oral, Diet | |
206 | Diesel engine exhaust | NA | Information reviewed but value not estimated. Refer to IRIS Summary. | |||||
207 | Diethyl phthalate | 84-66-2 | Not Assessed under the IRIS program. | |||||
208 | Diethyl sulfate | 64-67-5 | Not Assessed under the IRIS program. | |||||
209 | Diethyl-p-nitrophenylphosphate | 311-45-5 | Not Assessed under the IRIS program. | |||||
210 | Diethylene glycol dinitrate (DEGDN) | 693-21-0 | Not Assessed under the IRIS program. | |||||
211 | Difenzoquat | 43222-48-6 | Not Assessed under the IRIS program. | |||||
212 | Diflubenzuron | 35367-38-5 | Not Assessed under the IRIS program. | |||||
213 | 1,1-Difluoroethane | 75-37-6 | Not Assessed under the IRIS program. | |||||
214 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | Not Assessed under the IRIS program. | |||||
215 | Dimethipin | 55290-64-7 | Not Assessed under the IRIS program. | |||||
216 | Dimethoate | 60-51-5 | Not Assessed under the IRIS program. | |||||
217 | Dimethyl phthalate | 131-11-3 | Not Assessed under the IRIS program. | |||||
218 | Dimethyl sulfate | 77-78-1 | Not Assessed under the IRIS program. | |||||
219 | Dimethyl terephthalate (DMT) | 120-61-6 | Not Assessed under the IRIS program. | |||||
220 | Dimethylamine | 124-40-3 | Not Assessed under the IRIS program. | |||||
221 | N-N-Dimethylaniline | 121-69-7 | Not Assessed under the IRIS program. | |||||
222 | 3,3-Dimethylbenzidine | 119-93-7 | Not Assessed under the IRIS program. | |||||
223 | N,N-Dimethylformamide | 68-12-2 | Not Assessed under the IRIS program. | |||||
224 | 3,4-Dimethylphenol | 95-65-8 | Not Assessed under the IRIS program. | |||||
225 | 2,6-Dimethylphenol | 576-26-1 | Not Assessed under the IRIS program. | |||||
226 | 2,4-Dimethylphenol | 105-67-9 | Not Assessed under the IRIS program. | |||||
227 | 4,6-Dinitro-o-cyclohexyl phenol | 131-89-5 | Not Assessed under the IRIS program. | |||||
228 | m-Dinitrobenzene | 99-65-0 | Not Assessed under the IRIS program. | |||||
229 | o-Dinitrobenzene | 528-29-0 | Not Assessed under the IRIS program. | |||||
230 | 2,4-Dinitrophenol | 51-28-5 | Not Assessed under the IRIS program. | |||||
231 | 2,4-Dinitrotoluene | 121-14-2 | Not Assessed under the IRIS program. | |||||
232 | 2,4-/2,6-Dinitrotoluene mixture | NA | Not Assessed under the IRIS program. | |||||
233 | Dinoseb | 88-85-7 | Not Assessed under the IRIS program. | |||||
234 | 1,4-Dioxane | 123-91-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | |||||
235 | Diphenamid | 957-51-7 | Not Assessed under the IRIS program. | |||||
236 | Diphenylamine | 122-39-4 | Not Assessed under the IRIS program. | |||||
237 | 1,2-Diphenylhydrazine | 122-66-7 | Hepatocellular carcinomas and neoplastic liver nodules | Linearized multistage procedure, extra risk | per µg /m3 | 2.2x10-4 | Oral, Diet | |
238 | Diquat | 85-00-7 | Not Assessed under the IRIS program. | |||||
239 | Disulfoton | 298-04-4 | Not Assessed under the IRIS program. | |||||
240 | 1,4-Dithiane | 505-29-3 | Not Assessed under the IRIS program. | |||||
241 | Diuron | 330-54-1 | Not Assessed under the IRIS program. | |||||
242 | Dodine | 2439-10-3 | Not Assessed under the IRIS program. | |||||
243 | Endosulfan | 115-29-7 | Not Assessed under the IRIS program. | |||||
244 | Endothall | 145-73-3 | Not Assessed under the IRIS program. | |||||
245 | Endrin | 72-20-8 | Not Assessed under the IRIS program. | |||||
246 | Epichlorohydrin | 106-89-8 | Nasal cavity tumors | Linearized multistage procedure, extra risk | per µg /m3 | 1.2x10-6 | Inhalation | |
247 | 1,2-Epoxybutane (EBU) | 106-88-7 | Not Assessed under the IRIS program. | |||||
248 | Ethephon | 16672-87-0 | Not Assessed under the IRIS program. | |||||
249 | Ethion | 563-12-2 | Not Assessed under the IRIS program. | |||||
250 | 2-Ethoxyethanol | 110-80-5 | Not Assessed under the IRIS program. | |||||
251 | Ethyl acetate | 141-78-6 | Not Assessed under the IRIS program. | |||||
252 | Ethyl carbamate | 51-79-6 | Not Assessed under the IRIS program. | |||||
253 | Ethyl chloride | 75-00-3 | Not Assessed under the IRIS program. | |||||
254 | S-Ethyl dipropylthiocarbamate (EPTC) | 759-94-4 | Not Assessed under the IRIS program. | |||||
255 | Ethyl ether | 60-29-7 | Not Assessed under the IRIS program. | |||||
256 | Ethyl p-nitrophenyl phenylphosphorothioate (EPN) | 2104-64-5 | Not Assessed under the IRIS program. | |||||
257 | Ethylbenzene | 100-41-4 | Not Assessed under the IRIS program. | |||||
258 | Ethylene diamine | 107-15-3 | Not Assessed under the IRIS program. | |||||
259 | Ethylene glycol | 107-21-1 | Not Assessed under the IRIS program. | |||||
260 | Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) | 111-76-2 | Information reviewed but value not estimated. Refer to IRIS Summary. | |||||
261 | Ethylene thiourea (ETU) | 96-45-7 | Not Assessed under the IRIS program. | |||||
262 | Ethyleneimine | 151-56-4 | Not Assessed under the IRIS program. | |||||
263 | Ethylphthalyl ethylglycolate (EPEG) | 84-72-0 | Not Assessed under the IRIS program. | |||||
264 | Express | 101200-48-0 | Not Assessed under the IRIS program. | |||||
265 | Fenamiphos | 22224-92-6 | Not Assessed under the IRIS program. | |||||
266 | Fluometuron | 2164-17-2 | Not Assessed under the IRIS program. | |||||
267 | Fluoranthene | 206-44-0 | Not Assessed under the IRIS program. | |||||
268 | Fluorene | 86-73-7 | Not Assessed under the IRIS program. | |||||
269 | Fluorine (soluble fluoride) | 7782-41-4 | Not Assessed under the IRIS program. | |||||
270 | Fluridone | 59756-60-4 | Not Assessed under the IRIS program. | |||||
271 | Flurprimidol | 56425-91-3 | Not Assessed under the IRIS program. | |||||
272 | Flutolanil | 66332-96-5 | Not Assessed under the IRIS program. | |||||
273 | Fluvalinate | 69409-94-5 | Not Assessed under the IRIS program. | |||||
274 | Folpet | 133-07-3 | Not Assessed under the IRIS program. | |||||
275 | Fomesafen | 72178-02-0 | Not Assessed under the IRIS program. | |||||
276 | Fonofos | 944-22-9 | Not Assessed under the IRIS program. | |||||
277 | Formaldehyde | 50-00-0 | Squamous cell carcinoma | Linearized multistage procedure, additional risk | per µg /m3 | 1.3x10-5 | Inhalation | |
278 | Formic acid | 64-18-6 | Not Assessed under the IRIS program. | |||||
279 | Fosetyl-al | 39148-24-8 | Not Assessed under the IRIS program. | |||||
280 | Furan | 110-00-9 | Not Assessed under the IRIS program. | |||||
281 | Furfural | 98-01-1 | Not Assessed under the IRIS program. | |||||
282 | Furmecyclox | 60568-05-0 | Not Assessed under the IRIS program. | |||||
283 | Glufosinate-ammonium | 77182-82-2 | Not Assessed under the IRIS program. | |||||
284 | Glycidaldehyde | 765-34-4 | Not Assessed under the IRIS program. | |||||
285 | Glyphosate | 1071-83-6 | Not Assessed under the IRIS program. | |||||
286 | Haloxyfop-methyl | 69806-40-2 | Not Assessed under the IRIS program. | |||||
287 | Harmony | 79277-27-3 | Not Assessed under the IRIS program. | |||||
288 | Heptachlor | 76-44-8 | Hepatocellular carcinomas | Linearized multistage procedure, extra risk | per µg/m3 | 1.3x10-3 | Oral, Diet | |
289 | Heptachlor epoxide | 1024-57-3 | Hepatocellular carcinomas | Linearized multistage procedure, extra risk | per µg/m3 | 2.6x10-3 | Oral, Diet | |
290 | n-Heptane | 142-82-5 | Not Assessed under the IRIS program. | |||||
291 | Hexabromobenzene | 87-82-1 | Not Assessed under the IRIS program. | |||||
292 | Hexabromodiphenyl ether | 36483-60-0 | Not Assessed under the IRIS program. | |||||
293 | 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) | 68631-49-2 | Not Assessed under the IRIS program. | |||||
294 | Hexachlorobenzene | 118-74-1 | Hepatocellular carcinoma | Linearized multistage, extra risk | per µg /m3 | 4.6x10-4 | Oral, Diet | |
295 | Hexachlorobutadiene | 87-68-3 | Renal tubular adenomas and adenocarcinomas | Linearized multistage procedure, extra risk | per µg /m3 | 2.2x10-5 | Oral, Diet | |
296 | alpha-Hexachlorocyclohexane (alpha-HCH) | 319-84-6 | Hepatic nodules and hepatocellular carcinomas | Linearized multistage procedure, extra risk | per µg /m3 | 1.8x10-3 | Oral, Diet | |
297 | beta-Hexachlorocyclohexane (beta-HCH) | 319-85-7 | Hepatic nodules and hepatocellular carcinomas | Linearized multistage procedure, extra risk | per µg /m3 | 5.3x10-4 | Oral, Diet | |
298 | delta-Hexachlorocyclohexane (delta-HCH) | 319-86-8 | Not Assessed under the IRIS program. | |||||
299 | epsilon-Hexachlorocyclohexane (epsilon-HC) | 6108-10-7 | Not Assessed under the IRIS program. | |||||
300 | gamma-Hexachlorocyclohexane (gamma-HCH) | 58-89-9 | Not Assessed under the IRIS program. | |||||
301 | technical Hexachlorocyclohexane (t-HCH) | 608-73-1 | Liver nodules and hepatocellular carcinomas | Linearized multistage procedure | per µg /m3 | 5.1x10-4 | Oral, Diet | |
302 | Hexachlorocyclopentadiene (HCCPD) | 77-47-4 | Not Assessed under the IRIS program. | |||||
303 | Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD | 57653-85-7 | Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas) | Linearized multistage procedure, extra risk | per µg /m3 | 1.3 | Oral, Gavage | |
304 | Hexachloroethane | 67-72-1 | Information reviewed but value not estimated. Refer to IRIS Summary. | |||||
305 | Hexachlorophene | 70-30-4 | Not Assessed under the IRIS program. | |||||
306 | Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | 121-82-4 | Not Assessed under the IRIS program. | |||||
307 | 1,6-Hexamethylene diisocyanate | 822-06-0 | Not Assessed under the IRIS program. | |||||
308 | n-Hexane | 110-54-3 | Not Assessed under the IRIS program. | |||||
309 | 2-Hexanone | 591-78-6 | Not Assessed under the IRIS program. | |||||
310 | Hexazinone | 51235-04-2 | Not Assessed under the IRIS program. | |||||
311 | Hydrazine/Hydrazine sulfate | 302-01-2 | Nasal cavity adenoma or adenocarcinoma | Linearized multistage procedure, extra risk | per µg /m3 | 4.9x10-3 | Inhalation | |
312 | Hydrogen Cyanide and Cyanide Salts | Various | Not Assessed under the IRIS program. | |||||
313 | Hydrogen chloride | 7647-01-0 | Not Assessed under the IRIS program. | |||||
314 | Hydrogen sulfide | 7783-06-4 | Not Assessed under the IRIS program. | |||||
315 | Hydroquinone | 123-31-9 | Not Assessed under the IRIS program. | |||||
316 | Imazalil | 35554-44-0 | Not Assessed under the IRIS program. | |||||
317 | Imazaquin | 81335-37-7 | Not Assessed under the IRIS program. | |||||
318 | Indeno[1,2,3-cd]pyrene | 193-39-5 | Not Assessed under the IRIS program. | |||||
319 | Iprodione | 36734-19-7 | Not Assessed under the IRIS program. | |||||
320 | Isobutyl alcohol | 78-83-1 | Not Assessed under the IRIS program. | |||||
321 | Isophorone | 78-59-1 | Not Assessed under the IRIS program. | |||||
322 | Isopropalin | 33820-53-0 | Not Assessed under the IRIS program. | |||||
323 | Isopropyl methyl phosphonic acid (IMPA) | 1832-54-8 | Not Assessed under the IRIS program. | |||||
324 | Isoxaben | 82558-50-7 | Not Assessed under the IRIS program. | |||||
325 | Lactofen | 77501-63-4 | Not Assessed under the IRIS program. | |||||
326 | Lead and compounds (inorganic) | 7439-92-1 | Not Assessed under the IRIS program. | |||||
327 | d-Limonene | 5989-27-5 | Not Assessed under the IRIS program. | |||||
328 | Linuron | 330-55-2 | Not Assessed under the IRIS program. | |||||
329 | Londax | 83055-99-6 | Not Assessed under the IRIS program. | |||||
330 | Malathion | 121-75-5 | Not Assessed under the IRIS program. | |||||
331 | Maleic anhydride | 108-31-6 | Not Assessed under the IRIS program. | |||||
332 | Maleic hydrazide | 123-33-1 | Not Assessed under the IRIS program. | |||||
333 | Maneb | 12427-38-2 | Not Assessed under the IRIS program. | |||||
334 | Manganese | 7439-96-5 | Not Assessed under the IRIS program. | |||||
335 | Mepiquat chloride | 24307-26-4 | Not Assessed under the IRIS program. | |||||
336 | Mercuric chloride (HgCl2) | 7487-94-7 | Not Assessed under the IRIS program. | |||||
337 | Mercury, elemental | 7439-97-6 | Not Assessed under the IRIS program. | |||||
338 | Merphos | 150-50-5 | Not Assessed under the IRIS program. | |||||
339 | Merphos oxide | 78-48-8 | Not Assessed under the IRIS program. | |||||
340 | Metalaxyl | 57837-19-1 | Not Assessed under the IRIS program. | |||||
341 | Methacrylonitrile | 126-98-7 | Not Assessed under the IRIS program. | |||||
342 | Methamidophos | 10265-92-6 | Not Assessed under the IRIS program. | |||||
343 | Methanol | 67-56-1 | Not Assessed under the IRIS program. | |||||
344 | Methidathion | 950-37-8 | Not Assessed under the IRIS program. | |||||
345 | Methomyl | 16752-77-5 | Not Assessed under the IRIS program. | |||||
346 | Methoxychlor | 72-43-5 | Not Assessed under the IRIS program. | |||||
347 | 2-Methoxyethanol | 109-86-4 | Not Assessed under the IRIS program. | |||||
348 | Methyl acrylate | 96-33-3 | Not Assessed under the IRIS program. | |||||
349 | Methyl chloride | 74-87-3 | Not Assessed under the IRIS program. | |||||
350 | Methyl chlorocarbonate | 79-22-1 | Not Assessed under the IRIS program. | |||||
351 | Methyl ethyl ketone (MEK) | 78-93-3 | Not Assessed under the IRIS program. | |||||
352 | Methyl iodide | 74-88-4 | Not Assessed under the IRIS program. | |||||
353 | Methyl isobutyl ketone (MIBK) | 108-10-1 | Not Assessed under the IRIS program. | |||||
354 | Methyl isocyanate | 624-83-9 | Not Assessed under the IRIS program. | |||||
355 | Methyl methacrylate | 80-62-6 | Not Assessed under the IRIS program. | |||||
356 | Methyl parathion | 298-00-0 | Not Assessed under the IRIS program. | |||||
357 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | Not Assessed under the IRIS program. | |||||
358 | 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) | 94-81-5 | Not Assessed under the IRIS program. | |||||
359 | 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) | 93-65-2 | Not Assessed under the IRIS program. | |||||
360 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | Not Assessed under the IRIS program. | |||||
361 | Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) | 101-68-8 | Not Assessed under the IRIS program. | |||||
362 | 4,4'-Methylene bis(N,N'-dimethyl)aniline | 101-61-1 | Not Assessed under the IRIS program. | |||||
363 | Methylmercury (MeHg) | 22967-92-6 | Not Assessed under the IRIS program. | |||||
364 | 2-Methylnaphthalene | 91-57-6 | Not Assessed under the IRIS program. | |||||
365 | 2-Methylphenol | 95-48-7 | Not Assessed under the IRIS program. | |||||
366 | 4-Methylphenol | 106-44-5 | Not Assessed under the IRIS program. | |||||
367 | 3-Methylphenol | 108-39-4 | Not Assessed under the IRIS program. | |||||
368 | Metolachlor | 51218-45-2 | Not Assessed under the IRIS program. | |||||
369 | Metribuzin | 21087-64-9 | Not Assessed under the IRIS program. | |||||
370 | Mirex | 2385-85-5 | Not Assessed under the IRIS program. | |||||
371 | Molinate | 2212-67-1 | Not Assessed under the IRIS program. | |||||
372 | Molybdenum | 7439-98-7 | Not Assessed under the IRIS program. | |||||
373 | Monochloramine | 10599-90-3 | Not Assessed under the IRIS program. | |||||
374 | Naled | 300-76-5 | Not Assessed under the IRIS program. | |||||
375 | Naphthalene | 91-20-3 | Information reviewed but value not estimated. Refer to IRIS Summary. | |||||
376 | Napropamide | 15299-99-7 | Not Assessed under the IRIS program. | |||||
377 | Nickel carbonyl | 13463-39-3 | Not Assessed under the IRIS program. | |||||
378 | Nickel refinery dust | NA | Lung cancer | Additive and multiplicative | per µg /m3 | 2.4x10-4 | Inhalation | |
379 | Nickel subsulfide | 12035-72-2 | Lung cancer | Additive and multiplicative | per µg /m3 | 4.8x10-4 | Inhalation | |
380 | Nickel, soluble salts | NA | Not Assessed under the IRIS program. | |||||
381 | Nitrapyrin | 1929-82-4 | Not Assessed under the IRIS program. | |||||
382 | Nitrate | 14797-55-8 | Not Assessed under the IRIS program. | |||||
383 | Nitric oxide | 10102-43-9 | Not Assessed under the IRIS program. | |||||
384 | Nitrite | 14797-65-0 | Not Assessed under the IRIS program. | |||||
385 | Nitrobenzene | 98-95-3 | Liver hepatocellular adenomas or carcinomas, kidney tubular adenomas or carcinomas, thyroid follicular cell adenomas or carcinomas | Multistage model with linear extrapolation from the POD (LEC10). | per µg /m3 | 4x10-5 | Inhalation | |
386 | Nitrogen dioxide | 10102-44-0 | Not Assessed under the IRIS program. | |||||
387 | Nitroguanidine | 556-88-7 | Not Assessed under the IRIS program. | |||||
388 | p-Nitrophenol | 100-02-7 | Not Assessed under the IRIS program. | |||||
389 | 2-Nitropropane | 79-46-9 | Not Assessed under the IRIS program. | |||||
390 | N-Nitroso-N-methylethylamine | 10595-95-6 | Not Assessed under the IRIS program. | |||||
391 | N-Nitroso-di-n-butylamine | 924-16-3 | Bladder and esophagus tumors | Linearized multistage procedure, extra risk | per µg /m3 | 1.6x10-3 | Oral, Drinking water | |
392 | N-Nitrosodi-N-propylamine | 621-64-7 | Not Assessed under the IRIS program. | |||||
393 | N-Nitrosodiethanolamine | 1116-54-7 | Not Assessed under the IRIS program. | |||||
394 | N-Nitrosodiethylamine | 55-18-5 | Liver tumors | Weibull, extra risk | per µg /m3 | 4.3x10-2 | Oral, Drinking water | |
395 | N-Nitrosodimethylamine | 62-75-9 | Liver tumors | Weibull, extra risk | per µg /m3 | 1.4x10-2 | Oral, Drinking water | |
396 | N-Nitrosodiphenylamine | 86-30-6 | Not Assessed under the IRIS program. | |||||
397 | N-Nitrosopyrrolidine | 930-55-2 | Hepatocellular carcinoma and adenoma | Linearized multistage procedure, extra risk | per µg /m3 | 6.1x10-4 | Oral, Diet | |
398 | Nonabromodiphenyl ether | 63936-56-1 | Not Assessed under the IRIS program. | |||||
399 | Norflurazon | 27314-13-2 | Not Assessed under the IRIS program. | |||||
400 | NuStar | 85509-19-9 | Not Assessed under the IRIS program. | |||||
401 | Octabromodiphenyl ether | 32536-52-0 | Not Assessed under the IRIS program. | |||||
402 | Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) | 2691-41-0 | Not Assessed under the IRIS program. | |||||
403 | Oryzalin | 19044-88-3 | Not Assessed under the IRIS program. | |||||
404 | Oxadiazon | 19666-30-9 | Not Assessed under the IRIS program. | |||||
405 | Oxamyl | 23135-22-0 | Not Assessed under the IRIS program. | |||||
406 | Oxyfluorfen | 42874-03-3 | Not Assessed under the IRIS program. | |||||
407 | Paclobutrazol | 76738-62-0 | Not Assessed under the IRIS program. | |||||
408 | Paraquat | 1910-42-5 | Not Assessed under the IRIS program. | |||||
409 | Parathion | 56-38-2 | Not Assessed under the IRIS program. | |||||
410 | Pendimethalin | 40487-42-1 | Not Assessed under the IRIS program. | |||||
411 | Pentabromodiphenyl ether | 32534-81-9 | Not Assessed under the IRIS program. | |||||
412 | 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) | 60348-60-9 | Not Assessed under the IRIS program. | |||||
413 | Pentachlorobenzene | 608-93-5 | Not Assessed under the IRIS program. | |||||
414 | Pentachlorocyclopentadiene | 25329-35-5 | Not Assessed under the IRIS program. | |||||
415 | Pentachloronitrobenzene (PCNB) | 82-68-8 | Not Assessed under the IRIS program. | |||||
416 | Pentachlorophenol | 87-86-5 | Not Assessed under the IRIS program. | |||||
417 | Pentafluoroethane | 354-33-6 | Not Assessed under the IRIS program. | |||||
418 | Perchlorate (ClO4) and Perchlorate Salts | 7790-98-9 | Not Assessed under the IRIS program. | |||||
419 | Permethrin | 52645-53-1 | Not Assessed under the IRIS program. | |||||
420 | Phenanthrene | 85-01-8 | Not Assessed under the IRIS program. | |||||
421 | Phenmedipham | 13684-63-4 | Not Assessed under the IRIS program. | |||||
422 | Phenol | 108-95-2 | Not Assessed under the IRIS program. | |||||
423 | m-Phenylenediamine | 108-45-2 | Not Assessed under the IRIS program. | |||||
424 | Phenylmercuric acetate | 62-38-4 | Not Assessed under the IRIS program. | |||||
425 | Phosalone | 2310-17-0 | Not Assessed under the IRIS program. | |||||
426 | Phosgene | 75-44-5 | Not Assessed under the IRIS program. | |||||
427 | Phosmet | 732-11-6 | Not Assessed under the IRIS program. | |||||
428 | Phosphine | 7803-51-2 | Not Assessed under the IRIS program. | |||||
429 | Phosphoric acid | 7664-38-2 | Not Assessed under the IRIS program. | |||||
430 | Phthalic anhydride | 85-44-9 | Not Assessed under the IRIS program. | |||||
431 | Picloram | 1918-02-1 | Not Assessed under the IRIS program. | |||||
432 | Pirimiphos-methyl | 29232-93-7 | Not Assessed under the IRIS program. | |||||
433 | Polychlorinated biphenyls (PCBs) | 1336-36-3 | Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas | Linear extrapolation below LED10s | per µg /m3 | 1x10-4 | Oral, Diet | |
434 | Potassium cyanide | 151-50-8 | Not Assessed under the IRIS program. | |||||
435 | Potassium silver cyanide | 506-61-6 | Not Assessed under the IRIS program. | |||||
436 | Prochloraz | 67747-09-5 | Not Assessed under the IRIS program. | |||||
437 | Prometon | 1610-18-0 | Not Assessed under the IRIS program. | |||||
438 | Prometryn | 7287-19-6 | Not Assessed under the IRIS program. | |||||
439 | Pronamide | 23950-58-5 | Not Assessed under the IRIS program. | |||||
440 | Propachlor | 1918-16-7 | Not Assessed under the IRIS program. | |||||
441 | Propanil | 709-98-8 | Not Assessed under the IRIS program. | |||||
442 | Propargite | 2312-35-8 | Not Assessed under the IRIS program. | |||||
443 | Propargyl alcohol | 107-19-7 | Not Assessed under the IRIS program. | |||||
444 | Propazine | 139-40-2 | Not Assessed under the IRIS program. | |||||
445 | Propham | 122-42-9 | Not Assessed under the IRIS program. | |||||
446 | Propiconazole | 60207-90-1 | Not Assessed under the IRIS program. | |||||
447 | beta-Propiolactone | 57-57-8 | Not Assessed under the IRIS program. | |||||
448 | Propionaldehyde | 123-38-6 | Not Assessed under the IRIS program. | |||||
449 | Propylene glycol | 57-55-6 | Not Assessed under the IRIS program. | |||||
450 | Propylene glycol monoethyl ether | 52125-53-8 | Not Assessed under the IRIS program. | |||||
451 | Propylene glycol monomethyl ether (PGME) | 107-98-2 | Not Assessed under the IRIS program. | |||||
452 | Propylene oxide | 75-56-9 | Nasal cavity hemangioma or hemangiosarcoma | Linearized multistage procedure, extra risk | per µg /m3 | 3.7x10-6 | Inhalation | |
453 | Propyleneimine | 75-55-8 | Not Assessed under the IRIS program. | |||||
454 | Pursuit | 81335-77-5 | Not Assessed under the IRIS program. | |||||
455 | Pydrin | 51630-58-1 | Not Assessed under the IRIS program. | |||||
456 | Pyrene | 129-00-0 | Not Assessed under the IRIS program. | |||||
457 | Pyridine | 110-86-1 | Not Assessed under the IRIS program. | |||||
458 | Quinalphos | 13593-03-8 | Not Assessed under the IRIS program. | |||||
459 | Quinoline | 91-22-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | |||||
460 | Quinone | 106-51-4 | Not Assessed under the IRIS program. | |||||
461 | Radium 226,228 | 7440-14-4 | Not Assessed under the IRIS program. | |||||
462 | Radon 222 | 14859-67-7 | Not Assessed under the IRIS program. | |||||
463 | Refractory ceramic fibers | NA | Information reviewed but value not estimated. Refer to IRIS Summary. | |||||
464 | Resmethrin | 10453-86-8 | Not Assessed under the IRIS program. | |||||
465 | Rotenone | 83-79-4 | Not Assessed under the IRIS program. | |||||
466 | Savey | 78587-05-0 | Not Assessed under the IRIS program. | |||||
467 | Selenious acid | 7783-00-8 | Not Assessed under the IRIS program. | |||||
468 | Selenium and Compounds | 7782-49-2 | Not Assessed under the IRIS program. | |||||
469 | Selenium sulfide | 7446-34-6 | Not Assessed under the IRIS program. | |||||
470 | Selenourea | 630-10-4 | Not Assessed under the IRIS program. | |||||
471 | Sethoxydim | 74051-80-2 | Not Assessed under the IRIS program. | |||||
472 | Silver | 7440-22-4 | Not Assessed under the IRIS program. | |||||
473 | Silver cyanide | 506-64-9 | Not Assessed under the IRIS program. | |||||
474 | Simazine | 122-34-9 | Not Assessed under the IRIS program. | |||||
475 | Sodium azide | 26628-22-8 | Not Assessed under the IRIS program. | |||||
476 | Sodium cyanide | 143-33-9 | Not Assessed under the IRIS program. | |||||
477 | Sodium diethyldithiocarbamate | 148-18-5 | Not Assessed under the IRIS program. | |||||
478 | Sodium fluoroacetate | 62-74-8 | Not Assessed under the IRIS program. | |||||
479 | Strontium | 7440-24-6 | Not Assessed under the IRIS program. | |||||
480 | Strychnine | 57-24-9 | Not Assessed under the IRIS program. | |||||
481 | Styrene | 100-42-5 | Not Assessed under the IRIS program. | |||||
482 | Systhane | 88671-89-0 | Not Assessed under the IRIS program. | |||||
483 | Tebuthiuron | 34014-18-1 | Not Assessed under the IRIS program. | |||||
484 | Terbacil | 5902-51-2 | Not Assessed under the IRIS program. | |||||
485 | Terbutryn | 886-50-0 | Not Assessed under the IRIS program. | |||||
486 | Tetrabromodiphenyl ether | 40088-47-9 | Not Assessed under the IRIS program. | |||||
487 | 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) | 5436-43-1 | Not Assessed under the IRIS program. | |||||
488 | 1,2,4,5-Tetrachlorobenzene | 95-94-3 | Not Assessed under the IRIS program. | |||||
489 | Tetrachlorocyclopentadiene | 695-77-2 | Not Assessed under the IRIS program. | |||||
490 | 1,1,1,2-Tetrachloroethane | 630-20-6 | Hepatocellular adenoma or carcinoma | Linearized multistage procedure, extra risk | per µg /m3 | 7.4x10-6 | Oral, Gavage | |
491 | 1,1,2,2-Tetrachloroethane | 79-34-5 | Information reviewed but value not estimated. Refer to IRIS Summary. | |||||
492 | Tetrachloroethylene | 127-18-4 | Not Assessed under the IRIS program. | |||||
493 | 2,3,4,6-Tetrachlorophenol | 58-90-2 | Not Assessed under the IRIS program. | |||||
494 | Tetrachlorovinphos | 961-11-5 | Not Assessed under the IRIS program. | |||||
495 | Tetraethyl lead | 78-00-2 | Not Assessed under the IRIS program. | |||||
496 | Tetraethyldithiopyrophosphate | 3689-24-5 | Not Assessed under the IRIS program. | |||||
497 | 1,1,1,2-Tetrafluoroethane | 811-97-2 | Not Assessed under the IRIS program. | |||||
498 | Thallium (I), soluble salts | Various | Not Assessed under the IRIS program. | |||||
499 | Thallium acetate | 563-68-8 | Not Assessed under the IRIS program. | |||||
500 | Thallium carbonate | 6533-73-9 | Not Assessed under the IRIS program. | |||||
501 | Thallium chloride | 7791-12-0 | Not Assessed under the IRIS program. | |||||
502 | Thallium nitrate | 10102-45-1 | Not Assessed under the IRIS program. | |||||
503 | Thallium oxide | 1314-32-5 | Not Assessed under the IRIS program. | |||||
504 | Thallium selenite | 12039-52-0 | Not Assessed under the IRIS program. | |||||
505 | Thallium(I) sulfate | 7446-18-6 | Not Assessed under the IRIS program. | |||||
506 | Thiobencarb | 28249-77-6 | Not Assessed under the IRIS program. | |||||
507 | Thiophanate-methyl | 23564-05-8 | Not Assessed under the IRIS program. | |||||
508 | Thiram | 137-26-8 | Not Assessed under the IRIS program. | |||||
509 | Toluene | 108-88-3 | Not Assessed under the IRIS program. | |||||
510 | 2,4-/2,6-Toluene diisocyanate mixture (TDI) | 26471-62-5 | Not Assessed under the IRIS program. | |||||
511 | Toxaphene | 8001-35-2 | Hepatocellular carcinomas and neoplastic nodules | Linearized multistage procedure, extra risk | per µg /m3 | 3.2x10-4 | Oral, Diet | |
512 | Tralomethrin | 66841-25-6 | Not Assessed under the IRIS program. | |||||
513 | Triallate | 2303-17-5 | Not Assessed under the IRIS program. | |||||
514 | Triasulfuron | 82097-50-5 | Not Assessed under the IRIS program. | |||||
515 | 1,2,4-Tribromobenzene | 615-54-3 | Not Assessed under the IRIS program. | |||||
516 | Tribromochloromethane | 594-15-0 | Not Assessed under the IRIS program. | |||||
517 | Tribromodiphenyl ether | 49690-94-0 | Not Assessed under the IRIS program. | |||||
518 | Tributyltin oxide (TBTO) | 56-35-9 | Not Assessed under the IRIS program. | |||||
519 | 1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113) | 76-13-1 | Not Assessed under the IRIS program. | |||||
520 | Trichloroacetic acid | 76-03-9 | Information reviewed but value not estimated. Refer to IRIS Summary. | |||||
521 | 1,2,4-Trichlorobenzene | 120-82-1 | Not Assessed under the IRIS program. | |||||
522 | Trichlorocyclopentadiene | 77323-84-3 | Not Assessed under the IRIS program. | |||||
523 | 1,1,2-Trichloroethane | 79-00-5 | Hepatocellular carcinoma | Linearized multistage procedure, extra risk | per µg /m3 | 1.6x10-5 | Oral, Gavage | |
524 | 1,1,1-Trichloroethane | 71-55-6 | Information reviewed but value not estimated. Refer to IRIS Summary. | |||||
525 | Trichloroethylene | 79-01-6 | Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors | Low-dose linear extrapolation from the point of departure (LEC01) with a factor of 4 applied to include non-Hodgkin's lymphoma (NHL) and liver cancer risks, combined risk | per µg /m3 | 4.1x10-6 | Inhalation | |
526 | Trichlorofluoromethane | 75-69-4 | Not Assessed under the IRIS program. | |||||
527 | 2,4,5-Trichlorophenol | 95-95-4 | Not Assessed under the IRIS program. | |||||
528 | 2,4,6-Trichlorophenol | 88-06-2 | Leukemia | Linearized multistage procedure, extra risk | per µg /m3 | 3.1x10-6 | Oral,Diet | |
529 | 2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP) | 93-72-1 | Not Assessed under the IRIS program. | |||||
530 | 2,4,5-Trichlorophenoxyacetic acid (2,4,5-T) | 93-76-5 | Not Assessed under the IRIS program. | |||||
531 | 1,1,2-Trichloropropane | 598-77-6 | Not Assessed under the IRIS program. | |||||
532 | 1,2,3-Trichloropropane | 96-18-4 | Not Assessed under the IRIS program. | |||||
533 | Tricresol | 1319-77-3 | Not Assessed under the IRIS program. | |||||
534 | Tridiphane | 58138-08-2 | Not Assessed under the IRIS program. | |||||
535 | Triethylamine | 121-44-8 | Not Assessed under the IRIS program. | |||||
536 | Triethylene glycol monobutyl ether | 143-22-6 | Not Assessed under the IRIS program. | |||||
537 | Triethylene glycol monoethyl ether | 112-50-5 | Not Assessed under the IRIS program. | |||||
538 | Trifluralin | 1582-09-8 | Not Assessed under the IRIS program. | |||||
539 | 2,2,4-Trimethylpentane | 540-84-1 | Not Assessed under the IRIS program. | |||||
540 | 1,3,5-Trinitrobenzene | 99-35-4 | Not Assessed under the IRIS program. | |||||
541 | 2,4,6-Trinitrotoluene (TNT) | 118-96-7 | Not Assessed under the IRIS program. | |||||
542 | Uranium, natural | 7440-61-1 | Not Assessed under the IRIS program. | |||||
543 | Uranium, soluble salts | NA | Not Assessed under the IRIS program. | |||||
544 | Urea | 57-13-6 | Not Assessed under the IRIS program. | |||||
545 | Vanadium pentoxide | 1314-62-1 | Not Assessed under the IRIS program. | |||||
546 | Vernam | 1929-77-7 | Not Assessed under the IRIS program. | |||||
547 | Vinclozolin | 50471-44-8 | Not Assessed under the IRIS program. | |||||
548 | Vinyl acetate | 108-05-4 | Not Assessed under the IRIS program. | |||||
549 | Vinyl bromide | 593-60-2 | Not Assessed under the IRIS program. | |||||
550 | Vinyl chloride | 75-01-4 | Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules | LMS method | per µg /m3 | 4.4x10-6 | Inhalation | |
551 | Vinyl chloride | 75-01-4 | Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules | LED 10/ linear method | per µg /m3 | 4.4x10-6 | Inhalation | |
552 | Vinyl chloride | 75-01-4 | Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules | LMS method | per µg /m3 | 8.8x10-6 | Inhalation | |
553 | Vinyl chloride | 75-01-4 | Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules | LED 10/ linear method | per µg /m3 | 8.8x10-6 | Inhalation | |
554 | Warfarin | 81-81-2 | Not Assessed under the IRIS program. | |||||
555 | White phosphorus | 7723-14-0 | Not Assessed under the IRIS program. | |||||
556 | Xylenes | 1330-20-7 | Not Assessed under the IRIS program. | |||||
557 | Zinc and Compounds | 7440-66-6 | Not Assessed under the IRIS program. | |||||
558 | Zinc cyanide | 557-21-1 | Not Assessed under the IRIS program. | |||||
559 | Zinc phosphide | 1314-84-7 | Not Assessed under the IRIS program. | |||||
560 | Zineb | 12122-67-7 | Not Assessed under the IRIS program. |
Rationale
See also
References
Related files
<mfanonymousfilelist></mfanonymousfilelist>